Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Component Synergy Research Research into BPC-157 and TB-500 individually demonstrates their complementary mechanisms - BPC-157's vascular and protective effects pair with TB-500's cellular migration capabilities
Disabling CBP/p300-binding to NRF2 broadly attenuated NRF2 transcriptional activity resulting in an altered metabolic (depletion of glutathione) and lipidomic (specific depletion of triglycerides) cellular landscape
Dosing typically begins at a lower dose, suggested initiation of 20 units (0.2 mL) weekly for the first 4 weeks, then escalates according to a titration schedule: Weeks 14: Inject 20 units (0.2 mL) one time per week Weeks 58: Inject 40 units (0.4 mL) one time per week Weeks 912: Inject 70 units (0.7 mL) one time per week Weeks 1316: Inject 90 units (0.9 mL) one time per week Weeks 1720: Inject 120 units (1.2 mL) one time per week Week 21+: Inject 140 units (1.4 mL) one time per week Dosing may deviate from this pattern to accommodate patient-specific needs
Additionally, Tirzepatide has been found to lower fasting blood glucose levels & increase weight loss in participants who were overweight or obese at the start of clinical trials
This product has NOT been evaluated or approved by the MHRA
Nanobody-35 (Nb35) and HRV 3 C protease were in-house purified from E
